Antithyroid Drug Treatment in Graves' Disease

  • Chung, Jae Hoon
Citations

WEB OF SCIENCE

14
Citations

SCOPUS

20

초록

Graves' disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence after antithyroid drug (ATD) treatment is common. Recent studies have shown that the longer is the duration of use of ATD, the higher is the remission rate. Considering the relationship between clinical outcomes and iodine intake, recurrence of Graves' disease is more common in iodine-deficient areas than in iodine-sufficient areas. Iodine restriction in an iodine-excessive area does not improve the effectiveness of ATD or increase remission rates. Recently, Danish and Korean nationwide studies noted significantly higher prevalence of birth defects in newborns exposed to ATD during the first trimester compared to that of those who did not have such exposure. The prevalence of birth defects was lowest when propylthiouracil (PTU) was used and decreased by only 0.15% when methimazole was changed to PTU in the first trimester. Therefore, it is best not to use ATD in the first trimester or to change to PTU before pregnancy.

키워드

Graves disease; Antithyroid agents; Recurrence; Iodine; Congenital abnormalities; Pregnancy; AMERICAN THYROID ASSOCIATION; TOXIC NODULAR GOITER; TERM-FOLLOW-UP; IODINE INTAKE; HYPERTHYROIDISM; THERAPY; PROPYLTHIOURACIL; METHIMAZOLE; RECURRENCE; MANAGEMENT
제목
Antithyroid Drug Treatment in Graves' Disease
저자
Chung, Jae Hoon
DOI
10.3803/EnM.2021.1070
발행일
2021-06
유형
Review
저널명
Endocrinology and Metabolism
권
36
호
3
페이지
491 ~ 499